Casma Therapeutics, founded in 2018 and based in Cambridge, MA, is pioneering cellular degradation therapies through autophagy, targeting complex disease-causing elements like protein aggregates and organelles. Using its PHLYT™ platform, Casma reprograms autophagy to eliminate disease at its source, aiming to arrest or reverse conditions in oncology, inflammation, neurodegeneration, and metabolic disorders. The company’s innovative approach reflects its mission to deliver transformative therapeutics and its vision to restore health by addressing cellular damage. Recognized for its groundbreaking work, Casma fosters a culture of exploration and discovery, empowering its team, the "Casmaniacs," to redefine drug development.